Omniox

Omniox, Inc. is a San Francisco biotherapeutics company developing engineered protein oxygen carriers for diseases driven by tissue hypoxia. Its H-NOX platform technology produces OMX biologics designed to deliver oxygen selectively into pathologically hypoxic tissue, where low oxygen drives disease progression and worsens outcomes. The lead candidate, OMX-4.80P, is a PEGylated H-NOX oxygen carrier developed to reduce tumor hypoxia and sensitize glioblastoma and other solid tumors to radiotherapy. Founded in 2006, the company is at the investigational new drug (IND) stage, with published preclinical results in intracranial glioblastoma models and a phase 0 trial in canine brain cancer.

The engineered H-NOX scaffold binds oxygen with tuned affinity so it offloads only into severely hypoxic tissue rather than throughout the circulation, and the PEGylated form extends circulating half-life from roughly 1 hour to 30-35 hours with tumor accumulation out to 48 hours while remaining non-immunogenic in preclinical testing.